Free tool
FAERS Monitor: Uzedy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213586 or its brand name (Uzedy, Risperidone). Reports on generic versions are filed under their own applications.
Reports
64,028
Serious
49,562
77% of reports
Hospitalization
23,736
Death reported
5,886
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- gynaecomastia9,330
- off label use5,729
- drug ineffective5,316
- weight increased4,408
- drug interaction3,245
- product use in unapproved indication2,988
- emotional disorder2,879
- abnormal weight gain2,864
- condition aggravated2,411
- somnolence2,323
- toxicity to various agents2,293
- extrapyramidal disorder2,091
- emotional distress1,959
- suicide attempt1,898
- anxiety1,859
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 400 |
| 2005 | 506 |
| 2006 | 592 |
| 2007 | 580 |
| 2008 | 698 |
| 2009 | 1,200 |
| 2010 | 1,157 |
| 2011 | 1,587 |
| 2012 | 1,884 |
| 2013 | 1,528 |
| 2014 | 1,923 |
| 2015 | 4,815 |
| 2016 | 4,930 |
| 2017 | 6,885 |
| 2018 | 4,496 |
| 2019 | 4,735 |
| 2020 | 4,062 |
| 2021 | 3,694 |
| 2022 | 3,744 |
| 2023 | 3,527 |
| 2024 | 3,981 |
| 2025 | 3,972 |
| 2026 | 3,131 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,990,131 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| gynaecomastiaSignal | 9,330 | 141.4 | 138.1 | 909,748 |
| abnormal weight gainSignal | 2,864 | 98.8 | 94.8 | 213,140 |
| emotional disorderSignal | 2,879 | 33.7 | 32.5 | 83,016 |
| extrapyramidal disorderSignal | 2,091 | 30.1 | 28.8 | 53,932 |
| suicide attemptSignal | 1,898 | 10.6 | 10.1 | 15,990 |
| drug interactionSignal | 3,245 | 6.8 | 6.6 | 15,960 |
| weight increasedSignal | 4,408 | 6.6 | 6.4 | 20,644 |
| emotional distressSignal | 1,959 | 5.4 | 5.2 | 6,920 |
| toxicity to various agentsSignal | 2,293 | 4.5 | 4.3 | 6,235 |
| product use in unapproved indicationSignal | 2,988 | 4.0 | 3.9 | 6,708 |
| somnolenceSignal | 2,323 | 3.8 | 3.7 | 4,829 |
| condition aggravatedSignal | 2,411 | 2.6 | 2.5 | 2,425 |
| off label useSignal | 5,729 | 2.2 | 2.1 | 3,684 |
| anxietySignal | 1,859 | 2.2 | 2.1 | 1,155 |
| drug ineffective | 5,316 | 1.3 | 1.3 | 453 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.